Su Peng-Fei, Yu Jian-Chun
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.
Oncol Lett. 2022 Jun;23(6):172. doi: 10.3892/ol.2022.13292. Epub 2022 Apr 13.
Gastric cancer is one of the most common malignant tumor types in the world and the majority of patients have already reached the advanced stage at the time of initial diagnosis, owing to the subtle symptoms of gastric cancer in the early stage and the low rate of screening in the population. Surgical resection is one of the main treatments for advanced gastric cancer; however, the efficacy of surgery is limited by factors such as low radical resection rate and high distant metastasis rate. A large number of clinical trials have indicated that neoadjuvant therapy (NAT), which consists of neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and NAT combined with targeted therapy, may improve the therapeutic effect and prognosis of patients to different degrees. However, the benefit of NAT remains controversial due to the heterogeneity of clinical trials and gastric cancer itself. The present review summarizes the main research progress and key breakthrough of NAT for advanced gastric cancer and discusses its prospects.
胃癌是世界上最常见的恶性肿瘤类型之一，由于胃癌早期症状不明显且人群筛查率低，大多数患者在初次诊断时已处于晚期。手术切除是晚期胃癌的主要治疗方法之一；然而，手术疗效受到诸如根治性切除率低和远处转移率高等因素的限制。大量临床试验表明，新辅助治疗（NAT），包括新辅助化疗、新辅助放化疗以及NAT联合靶向治疗，可能在不同程度上改善患者的治疗效果和预后。然而，由于临床试验的异质性以及胃癌本身的特点，NAT的益处仍存在争议。本综述总结了晚期胃癌NAT的主要研究进展和关键突破，并探讨了其前景。
